Parkinson's Disease and Parkinsonism
Abstract
Parkinson's disease is a progressive neurodegenerative disease characterized by tremor and bradykinesia and is a common neurologic ailment. Male sex and advancing age are independent risk factors and, as the population ages, is taking an increasing toll on productivity and medical resources. There are a number of other extrapyramidal conditions that can make the diagnosis challenging. Unlike other neurodegenerative diseases, idiopathic Parkinson's disease has effective treatments that mitigate symptoms. Medications can improve day-to-day function and, in cases where medication does not give a sustained benefit or has significant side effects, treatments like deep brain stimulation result in improved quality of life.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MGF exhibits neuroprotective properties across multiple animal models of neurodegeneration, ischemia, and cognitive impairment.
“MGF exhibits robust neuroprotective properties across multiple animal models of neurodegeneration, ischemia and cognitive impairment.”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [132]
MGF's neuroprotective mechanisms include modulation of oxidative stress, mitochondrial protection, and anti-inflammatory signaling.
“Its mechanisms include the modulation of oxidative stress, mitochondrial protection and anti-inflammatory signaling (132).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [132]
The citation lists haven’t been fetched yet
References 55 · Cited by 823
- Authors
- Hayes, M. T.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Hayes, Michael T.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 132
- Issue
- 7
- Pages
- 802-807
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2921691260
- Cited by
- 823
- References
- 55
- Citations by year
- 2026: 112 · 2025: 164 · 2024: 183 · 2023: 139 · 2022: 104 · 2021: 79 · 2020: 25 · 2019: 4 · 2012: 1
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, parkinsonism, neurodegenerative diseases, tremor, bradykinesia, risk factors, extrapyramidal disorders, diagnosis, Parkinson's disease treatment, deep brain stimulation, quality of life
- MeSH terms
- Antiparkinson Agents, Diagnosis, Differential, Humans, Parkinson Disease, Parkinsonian Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
